Nervous system tumors include a wide variety of entities, classified according to histopathological features or
their location within the CNS. The high grade gliomas - anaplastic astrocytoma (WHO grade III) and glioblastoma (WHO
grade IV) – have a very poor prognosis and, despite intensive conventional therapy, the median survival rate for patients
with GBM is approximately 1 year. Investigation on molecular level of glioblastoma cells revealed over activation in response
to growth factors and subsequent activation of several signaling pathways such as EGFR-MAPK, PI-3K/Akt and
Notch. In the last years, there were an increasing number of patents disclosing new molecular methods to diagnose, stratify
or treat patients with glioblastoma, some of them being reviewed in the present article.